O1
|
First contact to first therapy ≤60 days
|
With an interval between first contact and first therapy ≤60 days
|
All patients with any recorded treatment and a contact§ ≤180 days
|
95
|
6 (56)
|
4 (35)
|
6 (56)
|
O2
|
From PET to surgery ≤ 45 days
|
With an interval between PET and surgery ≤45 days
|
All patients receiving lung surgery and having a PET within 3 months before
|
95
|
6 (57)
|
4 (35)
|
5 (46)
|
O3
|
Multidisciplinary evaluation
|
With multidisciplinary evaluation within 30 days before first treatment
|
All patients with any recorded treatment
|
95
|
6 (57)
|
5 (46)
|
6 (57)
|
O4
|
From thorax CT to surgery ≤45 days
|
With an interval between thorax CT and surgery ≤ 45 days
|
All patients receiving lung surgery and having a thorax CT within 3 months before
|
|
|
|
|
D1
|
Thorax CT at diagnosis
|
Thorax CT within 2 months from diagnosis
|
All patients
|
92
|
6 (57)
|
4 (26)
|
5 (36.5)
|
D2
|
Thorax CT before biopsy
|
With a thorax CT in the 30 days preceding broncoscopy or other biopsy procedure
|
All patients receiving a biopsy within 3 months before and one month after diagnosis
|
92
|
6 (57)
|
4.5 (36)
|
6 (47)
|
D3
|
Treatment with curative intent preceded by PET
|
With a PET record in the 3 months preceding surgery or chemoradiation
|
NSCLC patients in stage I-III receiving either surgery or concomitant/sequential chemoradiation
|
92
|
6 (57)
|
4 (36)
|
6 (47)
|
D4
|
Cyto-histologic confirmation
|
With cyto-histologic confirmation in the cancer register
|
All patients
|
92
|
6.5 (57)
|
4 (36)
|
6 (57)
|
D5
|
NSCLC Stage III patients assessed for metastasis before curative intent treatment
|
With a head CT/MR and PET/bone scan in the month preceding first therapy
|
NSCLC in stage III and receiving concomitant/sequential chemoradiation
|
92
|
6 (57)
|
5 (36)
|
6 (47)
|
D6
|
SCLC patients fully staged
|
With a thorax CT and abdominal CT/sonography and head CT/MR and PET/bone scan in the 3 months before diagnosis
|
All SCLC patients
|
92
|
6 (57)
|
5 (36)
|
6 (57)
|
S1
|
Survival after first surgery
|
Not deaceased within 30 days from first surgery
|
All patients receiving lung surgery
|
90
|
6 (67)
|
4.5 (26)
|
6 (57)
|
S2
|
Patients with a thorax CT ≤ 30 days before surgery
|
thorax CT in the 30 days before first surgery
|
All patients receiving lung surgery
|
90
|
6 (57)
|
4 (36)
|
6 (57)
|
S3
|
Functional evaluation before surgery
|
Lung functionality evaluation in the month before first surgery
|
All patients receiving lung surgery in stage I-IIIa
|
90
|
7 (67)
|
5 (36)
|
6 (57)
|
S4
|
Stage I-IIIA NSCLC patients undergoing curative intent surgery
|
Receiving surgery with presumed curative intent
|
NSCLC patients in stage I-IIIa
|
90
|
6 (57)
|
5 (36)
|
6 (57)
|
S5
|
Stage I-IIA NSCLC patients undergoing lobectomy
|
Receiving lobectomy as first surgery
|
NSCLC patients in stage I-IIa and receiving lung surgery
|
90
|
6 (57)
|
4 (36)
|
6 (56)
|
S6
|
No second surgery within 30 days
|
Not undergoing a second lung intervention within 30 days
|
All patients receiving lung surgery
|
90
|
6 (67)
|
4 (26)
|
6 (57)
|
S7
|
Hospital stay ≤ 14 days for first surgery
|
With an hospital stay ≤14 days and with no hospital access in the 30 days after discharge
|
All patients undergoing segmentectomy, lobectomy or pneumonectomy as their first lung surgery
|
90
|
6 (57)
|
4 (36)
|
6 (57)
|
M1
|
Stage II-III NSCLC patients receiving chemoradiation
|
Receiving concomitant or sequential chemoradiation
|
NSCLC patients in stage II-III that did not receive surgery
|
87
|
5 (56)
|
4 (35)
|
5 (46)
|
M2
|
SCLC patients undergoing medical oncologic therapy or radiotherapy
|
Receiving medical oncologic treatment and/or radiotherapy
|
SCLC patients not in stage IV
|
87
|
6 (57)
|
4 (35)
|
5 (46)
|
M3
|
Palliative care before death
|
Home-care, hospice or hospital admission for palliative care in the 3 months before death
|
All patients deceased at 31/12/2016
|
85
|
6 (67)
|
5 (36)
|
6 (57)
|
M4
|
Pain management before death
|
With an opioids prescription in the 3 months before death
|
All patients deceased at 31/12/2016
|
85
|
6 (57)
|
5 (36)
|
6 (47)
|
F1
|
Follow-up in year 2, 3, and 4 for surviving patients
|
With at least one follow-up visit or hospital admission in the year (excluding urgent admission and admission for medical oncologic treatment, radiotherapy or lung surgery)
|
Patients alive after 2, 3, and 4 years
|
85
|
6 (57)
|
5 (36)
|
6 (57)
|